

AJC/MMY/kmb
10/18/01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Scott K. Dessain and Richard A. Goldsby

1645 # 1645
RECEIVED

JAN 08 2002

TECH CENTER 1600/2900

Serial No.: 09/759,984

Group Art Unit: 1645

Filed: January 12, 2001

Examiner: Unknown

For: Production of Human Monoclonal Antibodies

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>10/18/01</u>	<u>K. Bastarache</u>
Date	Signature
<u>Kathleen M. Bastarache</u>	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

☒ Enclosed herewith is form PTO-1449:

- ☒ Copies of the cited references are enclosed. (AR-AZ; AR2-AZ2)
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ the enclosed English language abstract.

- ☐ Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Anne J. Collins

Anne J. Collins, Esq.
Registration No.: 40,564
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: 10/18/01

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0399.2012-001APPLICATION NO.
09/759,984INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

February 2, 2001

(Use several sheets if necessary)

APPLICANT
Scott K. DessainFILING DATE
12-Jan-01

GROUP

RECEIVED

JAN 08 2002

TECH CENTER 1600/290

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Bodnar, A. et al., "Extension of life-span by introduction of telomerase into normal human cells," <i>Science</i> , 279:349-352 (1998)
AS	Borrebaeck, C. et al., "Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?" <i>Immunol. Today</i> , 14:477-9 (1993)
AT	Chiorazzi, N. et al., "Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas," <i>J. Exp. Med.</i> , 156:930-5 (1982)

TECH CENTER 1500/2900

JAN 08 2002

RECEIVED

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0399.2012-001APPLICATION NO.
09/759,984INFORMATION DISCLOSURE CITATION
IN AN APPLICATIONAPPLICANT
Scott K. DessainFILING DATE
12-Jan-01

GROUP

February 2, 2001

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AU	deLange, T., "Telomeres and senescence: ending the debate," <i>Science</i> , 279:334-335 (1998)
AV	Edwards, P. et al., "A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line," <i>Eur. J. Immunol.</i> , 12:641-8 (1982)
AW	Greenberg, R. et al., "Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation," <i>Oncogene</i> , 16:1723-30 (1998)
AX	Ishii, Y. et al., "Telomerase activity in hybrids between telomerase-negative and telomerase-positive immortal human cells is repressed in the different complementation groups but not in the same complementation group of immortality," <i>Mech. Ageing Dev.</i> , 110:175-93 (1999)
AY	Katoh, M. et al., "A repressor function for telomerase activity in telomerase-negative immortal cells," <i>Mol. Carcinog.</i> , 21:17-25 (1998)
AZ	Köhler, G. and Milstein, C., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , 256:495-7 (1975)
AR2	Kim, N. and Wu, F., "Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP)," <i>Nucleic Acids Res.</i> , 25:2595-7 (1997)
AS2	Naviaux, R. et al., "The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses," <i>J. Virol.</i> , 70:5701-5 (1996)
AT2	Nakamura, T. et al., "Telomerase catalytic subunit homologs from fission yeast and human," <i>Science</i> , 277:955-9 (1997)

RECEIVED
JAN 08 2002
TEC. CENTER 1600/2900

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0399.2012-001APPLICATION NO.
09/759,984INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

February 2, 2001

(Use several sheets if necessary)


APPLICANT

Scott K. Dessain

FILING DATE

12-Jan-01

GROUP



U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AU2	Nowinski, R. et al., "Human monoclonal antibody against Forssman antigen," <i>Science</i> , 210:537-9 (1980)
AV2	Olsson, L. and Kaplan, H., "Human-human hybriomas producing monoclonal antibodies of predefined antigenic specificity," <i>Proc. Natl. Acad. Sci. USA</i> , 77:5429-31 (1980)
AW2	Pickering, J. and Gelder, C., "A human myeloma cell line that does not express immunoglobulin but yields a high frequency of antibody-secreting hybriomas," <i>J. Immunol.</i> , 129:406-412 (1982)
AX2	Shulman, M. et al., "A better cell line for making hybridomas secreting specific antibodies," <i>Nature</i> , 276:269-70 (1978)
AY2	Wright, W. et al., "Experimental elongation of telomeres extends the lifespan of immortal X normal cell hybrids," <i>Embo. J.</i> , 15:1734-41 (1996)
AZ2	Weng, N. et al., "Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential," <i>Immunity</i> , 9:151-7 (1998)

EXAMINER

DATE CONSIDERED